In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities
about
Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infectionsIn vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilisEfficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
P2860
In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
In vivo efficacies of quinolon ...... with in vitro susceptibilities
@ast
In vivo efficacies of quinolon ...... with in vitro susceptibilities
@en
type
label
In vivo efficacies of quinolon ...... with in vitro susceptibilities
@ast
In vivo efficacies of quinolon ...... with in vitro susceptibilities
@en
prefLabel
In vivo efficacies of quinolon ...... with in vitro susceptibilities
@ast
In vivo efficacies of quinolon ...... with in vitro susceptibilities
@en
P2860
P356
P1476
In vivo efficacies of quinolon ...... with in vitro susceptibilities
@en
P2093
P2860
P304
P356
10.1128/AAC.37.5.997
P407
P577
1993-05-01T00:00:00Z